Answers are grounded in this paper and cite their sources.
Variable proportions of hematopoietic cells that are heterozygous or homozygous for the JAK2 (V617) mutation can be found in patients with myeloproliferative neoplasms. In this perspective article, Dr. Passamonti and Rumi discuss the biologic and clinical significance of the mutant allele burden. See related paper on page 38.
No takes yet. Share an insight, caveat, or question.
Passamonti et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: